Conformation-specific effects of raf kinase inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7332-7341

  Wang, Xiaolun ^a   Kim, Joseph ^b  

^a Takeda San Diego Inc   (United States)

^b Blueprint Medicines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; 2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; AXITINIB; B RAF KINASE; B RAF KINASE INHIBITOR; CRIZOTINIB; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NILOTINIB; PAZOPANIB; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF KINASE INHIBITOR; RAF PROTEIN; RUXOLITINIB; SORAFENIB; SUNITINIB; TOFACITINIB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME CONFORMATION; HUMAN; IC 50; NONHUMAN; PROTEIN DOMAIN; PROTEIN TARGETING; REVIEW;

DIMERIZATION; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; RAF KINASES;

EID: 84866322592     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300613w     Document Type: Review

References (75)

1. Hait, W. N.; Hambley, T. W. Targeted cancer therapeutics Cancer Res. 2009, 69, 1263-1267
2. Li, R.; Stafford, J. A. Kinase Inhibitor Drugs, 1 st ed.; Wiley: Hoboken, NJ, 2009.
3. Taylor, S. S.; Kornev, A. P. Protein kinases: evolution of dynamic regulatory proteins Trends Biochem. Sci. 2011, 36, 65-77
4. Alton, G. R.; Lunney, E. A. Targeting the unactivated conformations of protein kinases for small molecule drug discovery Expert Opin. Drug Discovery 2008, 3, 595-605 (Pubitemid 351890672)
5. Backes, A.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinases. Part I: Exceptions from the traditional pharmacophore approach of type I inhibition Expert Opin. Drug Discovery 2008, 3, 1409-1425
6. Backes, A.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Small-molecule inhibitors binding to protein kinases. Part II: The novel pharmacophore approach of type II and type III inhibition Expert Opin. Drug Discovery 2008, 3, 1427-1449
7. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364 (Pubitemid 43936934)
8. Liao, J. L. Molecular targeting of protein kinases to optimize selectivity and resistance profiles of kinase inhibitors Curr. Top Med. Chem. 2007, 7, 1332-1335
9. Zuccotto, F.; Ardini, E.; Casale, E.; Angiolini, M. Through the "gatekeeper door": exploiting the active kinase conformation J. Med. Chem. 2010, 53, 2681-2694
10. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-target residence time and its implications for lead optimization Nat. Rev. Drug Discovery 2006, 5, 730-739 (Pubitemid 44323700)
11. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer Nature 2002, 417, 949-954 (Pubitemid 34716871)
12. Shepherd, C.; Puzanov, I.; Sosman, J. A. B-RAF inhibitors: an evolving role in the therapy of malignant melanoma Curr. Oncol. Rep. 2010, 12, 146-152
13. Puzanov, I.; Flaherty, K. T. Targeted molecular therapy in melanoma Semin. Cutaneous Med. Surg. 2010, 29, 196-201
14. Zambon, A.; Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Marais, R.; Springer, C. J. Small molecule inhibitors of BRAF in clinical trials Bioorg. Med. Chem. Lett. 2012, 22, 789-792. The structure of dabrafenib shown in this reference is incorrect and the correct structure can be found at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary= NCI%20Thesaurus&code=C82386
15. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; O'Dwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B. Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 2010, 363, 809-819
16. Chapman, P. B.; Hauschild, A.; Robert, C.; Haanen, J. B.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbe, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S. J.; Sosman, J. A.; Kirkwood, J. M.; Eggermont, A. M. M.; Dreno, B.; Nolop, K.; Li, J.; Nelson, B.; Hou, J.; Lee, R. J.; Flaherty, K. T.; McArthur, G. A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 2011, 364, 2507-2516
17. Kefford, R.; Arkenau, H.; Brown, M. P.; Millward, M.; Infante, J. R.; Long, G. V.; Ouellet, D.; Curtis, M.; Lebowitz, P. F.; Falchook, G. S. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors J. Clin. Oncol. 2010, 28 (Suppl.) Abstract 8503
18. FDA approved vemurafenib on August 17, 2011. http://www.cancer.gov/ cancertopics/druginfo/fda-vemurafenib.
19. Yang, H.; Higgins, B.; Kolinsky, K.; Packman, K.; Go, Z.; Iyer, R.; Kolis, S.; Zhao, S.; Lee, R.; Grippo, J. F.; Schostack, K.; Simcox, M. E.; Heimbrook, D.; Bollag, G.; Su, F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res. 2010, 70, 5518-5527
20. Heidorn, S. J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J. S.; Springer, C. J.; Pritchard, C.; Marais, R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 2010, 140, 209-221
21. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B. J.; Anderson, D. J.; Alvarado, R.; Ludlam, M. J. C.; Stokoe, D.; Gloor, S. L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Sideris, S.; Hoeflich, K. P.; Jaiswal, B. S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L. S.; Malek, S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 2010, 464, 431-435
22. Poulikakos, P. I.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 2010, 464, 427-430
23. Yun, C.-H.; Boggon, T. J.; Li, Y.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007, 11, 217-227 (Pubitemid 46349842)
24. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 2002, 277, 46265-46272 (Pubitemid 35417619)
25. Tokarski, J. S.; Newitt, J. A.; Chang, C. Y. J.; Cheng, J. D.; Wittekind, M.; Kiefer, S. E.; Kish, K.; Lee, F. Y. F.; Borzillerri, R.; Lombardo, L. J.; Xie, D.; Zhang, Y.; Klei, H. E. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Res. 2006, 66, 5790-5797 (Pubitemid 43927133)
26. Getlik, M.; Grütter, C.; Simard, J. R.; Klüter, S.; Rabiller, M.; Rode, H. B.; Robubi, A.; Rauh, D. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc J. Med. Chem. 2009, 52, 3915-3926
27. Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; Hunter, R. N.; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2 H -indazol-6-yl)methylamino] -2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor J. Med. Chem. 2008, 51, 4632-4640
28. Knowles, P. P.; Murray-Rust, J.; Kjaer, S.; Scott, R. P.; Hanrahan, S.; Santoro, M.; Ibáñez, C. F.; McDonald, N. Q. Structure and chemical inhibition of the RET tyrosine kinase domain J. Biol. Chem. 2006, 281, 33577-33587 (Pubitemid 46036738)
29. Cui, J. J.; Tran-Dubé, M.; Shen, H.; Nambu, M.; Kung, P.-P.; Pairish, M.; Jia, L.; Meng, J.; Funk, L.; Botrous, I.; McTigue, M.; Grodsky, N.; Ryan, K.; Padrique, E.; Alton, G.; Timofeevski, S.; Yamazaki, S.; Li, Q.; Zou, H.; Christensen, J.; Mroczkowski, B.; Bender, S.; Kania, R. S.; Edwards, M. P. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) J. Med. Chem. 2011, 54, 6342-6363
30. Ostojic, A.; Vrhovac, R.; Verstovsek, S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis Future Oncol. 2011, 7, 1035-1043
31. Gajiwala, K. S.; Wu, J. C.; Christensen, J.; Deshmukh, G. D.; Diehl, W.; DiNitto, J. P.; English, J. M.; Greig, M. J.; He, Y.-A.; Jacques, S. L.; Lunney, E. A.; McTigue, M.; Molina, D.; Quenzer, T.; Wells, P. A.; Yu, X.; Zhang, Y.; Zou, A.; Emmett, M. R.; Marshall, A. G.; Zhang, H.-M.; Demetri, G. D. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 1542-1547
32. Kutach, A. K.; Villaseñor, A. G.; Lam, D.; Belunis, C.; Janson, C.; Lok, S.; Hong, L.-N.; Liu, C.-M.; Deval, J.; Novak, T. J.; Barnett, J. W.; Chu, W.; Shaw, D.; Kuglstatter, A. Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation Chem. Biol. Drug Des. 2010, 76, 154-163
33. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 2002, 62, 4236-4243 (Pubitemid 34827278)
34. Cowan-Jacob, S. W.; Fendrich, G.; Floersheimer, A.; Furet, P.; Liebetanz, J.; Rummel, G.; Rheinberger, P.; Centeleghe, M.; Fabbro, D.; Manley, P. W. Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia Acta Crystallogr., Sect. D: Biol. Crystallogr. 2007, 63, 80-93 (Pubitemid 46141483)
35. Nagar, B.; Hantschel, O.; Young, M. A.; Scheffzek, K.; Veach, D.; Bornmann, W.; Clarkson, B.; Superti-Furga, G.; Kuriyan, J. Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell 2003, 112, 859-871 (Pubitemid 36378887)
36. Zhang, J.; Adrián, F. J.; Jahnke, W.; Cowan-Jacob, S. W.; Li, A. G.; Iacob, R. E.; Sim, T.; Powers, J.; Dierks, C.; Sun, F.; Guo, G.-R.; Ding, Q.; Okram, B.; Choi, Y.; Wojciechowski, A.; Deng, X.; Liu, G.; Fendrich, G.; Strauss, A.; Vajpai, N.; Grzesiek, S.; Tuntland, T.; Liu, Y.; Bursulaya, B.; Azam, M.; Manley, P. W.; Engen, J. R.; Daley, G. Q.; Warmuth, M.; Gray, N. S. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors Nature 2010, 463, 501-506
37. Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B.-C.; Wilson, K. P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J. Biol. Chem. 2004, 279, 31655-31663 (Pubitemid 39037836)
38. Wan, P. T. C.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 2004, 116, 855-867 (Pubitemid 38410730)
39. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Brüggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Azam, M.; Mohammed, A.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005, 7, 129-141 (Pubitemid 40248339)
40. Kania, R. S. In Kinase Inhibitor Drugs; Li, R.; Stafford, J. A., Eds.; Wiley: Hoboken, NJ, 2009; pp 167-201.
41. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) Cancer Res. 2004, 64, 6652
42. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West, B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y. J.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin, P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 2010, 467, 596-599
43. Williams, N. K.; Bamert, R. S.; Patel, O.; Wang, C.; Walden, P. M.; Wilks, A. F.; Fantino, E.; Rossjohn, J.; Lucet, I. S. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains J. Mol. Biol. 2009, 387, 219-232
44. Takle, A. K.; Brown, M. J. B.; Davies, S.; Dean, D. K.; Francis, G.; Gaiba, A.; Hird, A. W.; King, F. D.; Lovell, P. J.; Naylor, A.; Reith, A. D.; Steadman, J. G.; Wilson, D. M. The identification of potent and selective imidazole-based inhibitors of B-Raf kinase Bioorg. Med. Chem. Lett. 2006, 16, 378-381 (Pubitemid 41680630)
45. King, A. J.; Patrick, D. R.; Batorsky, R. S.; Ho, M. L.; Do, H. T.; Zhang, S. Y.; Kumar, R.; Rusnak, D. W.; Takle, A. K.; Wilson, D. M.; Hugger, E.; Wang, L.; Karreth, F.; Lougheed, J. C.; Lee, J.; Chau, D.; Stout, T. J.; May, E. W.; Rominger, C. M.; Schaber, M. D.; Luo, L.; Lakdawala, A. S.; Adams, J. L.; Contractor, R. G.; Smalley, K. S. M.; Herlyn, M.; Morrissey, M. M.; Tuveson, D. A.; Huang, P. S. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885 Cancer Res. 2006, 66, 11100-11105 (Pubitemid 46009933)
46. Smith, A. L.; DeMorin, F. F.; Paras, N. A.; Huang, Q.; Petkus, J. K.; Doherty, E. M.; Nixey, T.; Kim, J. L.; Whittington, D. A.; Epstein, L. F.; Lee, M. R.; Rose, M. J.; Babij, C.; Fernando, M.; Hess, K.; Le, Q.; Beltran, P.; Carnahan, J. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline J. Med. Chem. 2009, 52, 6189-6192
47. Carnahan, J.; Beltran, P. J.; Babij, C.; Le, Q.; Rose, M. J.; Vonderfecht, S.; Kim, J. L.; Smith, A. L.; Nagapudi, K.; Broome, M. A.; Fernando, M.; Kha, H.; Belmontes, B.; Radinsky, R.; Kendall, R.; Burgess, T. L. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth Mol. Cancer Ther. 2010, 9, 2399-2410
48. Hoeflich, K. P.; Herter, S.; Tien, J.; Wong, L.; Berry, L.; Chan, J.; O'Brien, C.; Modrusan, Z.; Seshagiri, S.; Lackner, M.; Stern, H.; Choo, E.; Murray, L.; Friedman, L. S.; Belvin, M. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression Cancer Res. 2009, 69, 3042-3051
49. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res. 2004, 64, 7099-7109 (Pubitemid 39331023)
50. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
51. Tsai, J.; Lee, J. T.; Wang, W.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kong, J.; Haass, N. K.; Sproesser, K.; Li, L.; Smalley, K. S. M.; Fong, D.; Zhu, Y.-L.; Marimuthu, A.; Nguyen, H.; Lam, B.; Liu, J.; Cheung, I.; Rice, J.; Suzuki, Y.; Luu, C.; Settachatgul, C.; Shellooe, R.; Cantwell, J.; Kim, S.-H.; Schlessinger, J.; Zhang, K. Y. J.; West, B. L.; Powell, B.; Habets, G.; Zhang, C.; Ibrahim, P. N.; Hirth, P.; Artis, D. R.; Herlyn, M.; Bollag, G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3041-3046 (Pubitemid 351723664)
52. Hall-Jackson, C. A.; Eyers, P. A.; Cohen, P.; Goedert, M.; Boyle, F. T.; Hewitt, N.; Plant, H.; Hedge, P. Paradoxical activation of Raf by a novel Raf inhibitor Chem. Biol. 1999, 6, 559-568 (Pubitemid 29380770)
53. Wang, X.; Berger, D. M.; Salaski, E. J.; Torres, N.; Dutia, M.; Hanna, C.; Hu, Y.; Levin, J. I.; Powell, D.; Wojciechowicz, D.; Collins, K.; Frommer, E.; Lucas, J. Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity J. Med. Chem. 2010, 53, 7874-7878
54. Besteman, E.; Bienvenu, J.-G.; Chaudhary, I.; Cukierski, M.; Marsh, B.; Surprenant, B. Epithelial Hyperplasia Induced by a Selective B-Raf Inhibitor, WYE-130600. Proceedings of the 101st Annual Meeting of the AACR; American Association for Cancer Research: Philadelphia, PA, 2010; Abstract 1677.
55. Wisler, J. A.; Afshari, C.; Fielden, M.; Zimmermann, C.; Taylor, S.; Carnahan, J.; Vonderfecht, S. Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat Toxicol. Pathol. 2011, 39, 809-822
56. Rajakulendran, T.; Sahmi, M.; Lefrancois, M.; Sicheri, F.; Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation Nature 2009, 461, 542-545
57. Zarrinkar, P. P.; Gunawardane, R. N.; Cramer, M. D.; Gardner, M. F.; Brigham, D.; Belli, B.; Karaman, M. W.; Pratz, K. W.; Pallares, G.; Chao, Q.; Sprankle, K. G.; Patel, H. K.; Levis, M.; Armstrong, R. C.; James, J.; Bhagwat, S. S. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Blood 2009, 114, 2984-2992
58. Smalley, K. S. M. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma Curr. Opin. Invest. Drugs 2010, 11, 699-706
59. Joseph, E. W.; Pratilas, C. A.; Poulikakos, P. I.; Tadi, M.; Wang, W.; Taylor, B. S.; Halilovic, E.; Persaud, Y.; Xing, F.; Viale, A.; Tsai, J.; Chapman, P. B.; Bollag, G.; Solit, D. B.; Rosen, N. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 14903-14908
60. Kaplan, F. M.; Shao, Y.; Mayberry, M. M.; Aplin, A. E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells Oncogene 2011, 30, 366-371
61. Halaban, R.; Zhang, W.; Bacchiocchi, A.; Cheng, E.; Parisi, F.; Ariyan, S.; Krauthammer, M.; McCusker, J. P.; Kluger, Y.; Sznol, M. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Pigm. Cell Melanoma Res. 2010, 23, 190-200
62. Farrar, M. A.; Alberol-Ila, J.; Perlmutter, R. M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization Nature 1996, 383, 178-181 (Pubitemid 26303982)
63. Luo, Z.; Tzivion, G.; Belshaw, P. J.; Vavvas, D.; Marshall, M.; Avruch, J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism Nature 1996, 383, 181-185 (Pubitemid 26303983)
64. Weber, C. K.; Slupsky, J. R.; Kalmes, H. A.; Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf Cancer Res. 2001, 61, 3595
65. Garnett, M. J.; Rana, S.; Paterson, H.; Barford, D.; Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization Mol. Cell 2005, 20, 963-969 (Pubitemid 41814884)
66. Rushworth, L. K.; Hindley, A. D.; O'Neill, E.; Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization Mol. Cell. Biol. 2006, 26, 2262
67. Dubauskas, Z.; Kunishige, J.; Prieto, V. G.; Jonasch, E.; Hwu, P.; Tannir, N. M. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib Clin. Genitourin. Cancer 2009, 7, 20-23
68. Dhomen, N.; Marais, R. BRAF signaling and targeted therapies in melanoma Hematol. Oncol. Clin. North Am. 2009, 23, 529-545, ix
69. Roskoski, R., Jr. RAF protein-serine/threonine kinases: structure and regulation Biochem. Biophys. Res. Commun. 2010, 399, 313-317
70. Udell, C. M.; Rajakulendran, T.; Sicheri, F.; Therrien, M. Mechanistic principles of RAF kinase signaling Cell. Mol. Life Sci. 2010, 68, 553-565
71. Infante, J. R.; Falchook, G. S.; Lawrence, D. P.; Weber, R. F.; Kefford, R. F.; Bendell, J. C.; Kurzrock, R.; Shapiro, G.; Kudchadkar, R. R.; Long, G. V.; Burris, H. A.; Kim, K. B.; Clements, A.; Peng, S.; Yi, B.; Allred, A. J.; Ouellet, D.; Patel, K.; Lebowitz, P. F.; Flaherty, K. T. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) J. Clin. Oncol. 2011, 29 (Suppl.) Abstract CRA8503
72. Corcoran, R. B.; Settleman, J.; Engelman, J. A. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers Oncotarget 2011, 2, 336-346
73. Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; Salton, M.; Dahlman, K. B.; Tadi, M.; Wargo, J. A.; Flaherty, K. T.; Kelley, M. C.; Misteli, T.; Chapman, P. B.; Sosman, J. A.; Graeber, T. G.; Ribas, A.; Lo, R. S.; Rosen, N.; Solit, D. B. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 2011, 480, 387-390
74. Hu, J.; Yu, H.; Kornev, A. P.; Zhao, J.; Filbert, E. L.; Taylor, S. S.; Shaw, A. S. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 6067-6072
75. McKay, M. M.; Ritt, D. A.; Morrison, D. K. RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling Curr. Biol. 2011, 21, 563-568